Regenerative Medicine Industry

The global regenerative medicine market was valued at USD 30.43 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 16.79% from 2024 to 2030. Key drivers for this growth include:

1. Advancements in Biological Therapies and Shift to Personalized Medicine:

   1. Recent progress in biological therapies has led to a growing shift from traditional treatment approaches to personalized medicinal strategies.

   2. Personalized medicine offers tailored treatments based on individual patient characteristics, leading to more precise and effective interventions. This shift has opened up new opportunities for companies involved in developing biological therapeutics, allowing them to innovate and meet the increasing demand for personalized treatment options.

2. Increased Focus on Regenerative Therapies Due to Degenerative Disorders:

   1. The rising prevalence of degenerative disorders, such as osteoarthritis, cardiovascular diseases, and neurodegenerative conditions, has intensified the focus on research and development (R&D) of novel regenerative therapies.

   2. Regenerative therapies, which aim to repair or replace damaged tissues and organs, are becoming crucial in addressing these disorders, driving the demand for innovative treatments that restore function and improve quality of life.

3. Impact of COVID-19 on the Regenerative Medicine and T-cell Therapy Market:

   1. The COVID-19 pandemic has significantly affected several markets, including the regenerative medicine and T-cell therapy manufacturing sectors.

   2. The SARS-CoV-2 crisis has disrupted the delivery of CAR T-cell therapies, which are critical for treating certain types of cancer. This disruption extends beyond patient care, affecting the administrative and logistical processes involved in therapy delivery and straining healthcare resources.

4. Challenges in Clinical Trials and Research Activities:

   1. The pandemic has also caused delays in clinical trials and other research activities, with many universities and research institutions slowing down the enrollment of participants and pausing ongoing studies. This has created temporary challenges for the advancement of regenerative medicine research and development.

5. Ongoing Market Expansion Despite Pandemic Challenges:

   1. Despite the setbacks caused by COVID-19, the regenerative medicine market continues to expand. Leading market players, such as Novartis, are working to ensure continued access to vital therapies.

   2. For example, Athersys, Inc.'s MultiStem, a regenerative therapy with significant potential for treating COVID-19-related complications, highlights the ongoing innovation and adaptation within the market as companies find ways to address both pandemic-related needs and broader regenerative medicine demands.

Gather more insights about the market drivers, restrains and growth of the Regenerative Medicine Market

Product Segmentation Insights

The therapeutics segment accounted for the largest market share, holding 76.24% in 2023. This is primarily due to the growing elderly population and the higher incidence of age-related and degenerative disorders. The increasing prevalence of diseases for which there are currently limited or no effective treatments, such as cancer, diabetes, and neurodegenerative conditions like age-related macular degeneration (AMD), has driven researchers to explore alternative therapeutic options.

1. Rising Disease Prevalence and Unmet Medical Needs:

   1. As the population ages, the occurrence of age-related conditions and degenerative disorders increases, driving the demand for innovative therapies.

   2. Diseases such as cancer, diabetes, and neurodegenerative disorders have high unmet medical needs, prompting researchers to develop new treatment alternatives, including regenerative medicine and biologics.

2. Notable Developments in CAR T-cell Therapy:

   1. In April 2022, Kite, a subsidiary of Gilead, received U.S. FDA approval for its CAR T-cell therapy product, Yescarta.

   2. Yescarta is designed for the treatment of refractory or relapsed large B-cell lymphoma, providing a new option for patients who have limited responses to existing treatments.

The banks segment is projected to experience the fastest compound annual growth rate (CAGR) of 17.34% from 2024 to 2030.

1. Role of Banks in Supporting Research:

   1. Banks, typically research-focused, are established with the goal of supporting scientific advancement by minimizing the effort, time, and cost associated with collecting, storing, and curating human tissues or cells for research purposes.

2. Growing Use of Banks in Medical Applications:

   1. With the increasing use of cell-based and tissue engineering approaches in medical applications, banks that provide these services for non-research purposes have also grown in number.

   2. The rising number of clinical trials for stem cell and tissue-based regenerative therapies reflects the expanding demand for these treatments, which in turn supports the growth of this segment.

3. Influence on Segment Growth:

   1. The combination of more clinical trials focused on stem cell and tissue-based therapies, along with the growing demand for regenerative medical treatments, is expected to significantly drive growth in the banks segment during the forecast period.

Order a free sample PDF of the Regenerative Medicine Market Intelligence Study, published by Grand View Research.